LARGO, Fla., Nov. 13, 2009 (GLOBE NEWSWIRE) -- GeoPharma, Inc. (Nasdaq:GORX) (the "Company") announced today that it will host a conference call to discuss the fiscal year 2010 second quarter, which ended September 30, 2009. Financial results will be released before the market opens on Tuesday, November 17, 2009 with the conference call to follow at 11:00 AM (ET). The conference call will be hosted by GeoPharma, Inc. CEO, Mihir Taneja and Sr. VP/CFO, Carol Dore-Falcone. Participants may dial in 15 minutes before the call is set to begin to register. The dial in number for participants is 1-719-325-2123. The Conference Confirmation code is 3306847.
Date: November 17, 2009 Time: 11:00 AM ET
Listen via Internet: http://gorx.client.shareholder.com/
Schedule this webcast into MS-Outlook calendar (click open when prompted):http://apps.shareholder.com/PNWOutlook/t.aspx?m=38418&k=A106D668
Telephone: 1-719-325-2123
Replay of the call will be available from 2 PM ET on November 17th, through Tuesday, December 1st. The Replay of the call may be heard by dialing 1-719-457-0820. The Replay Pass Code is 3306847. Participants may also choose to listen to the call via webcast through the link in the events and presentations section of the Investor Relations page of the GeoPharma website located at http://www.geopharmainc.com.
ABOUT GEOPHARMA, INC.: GeoPharma, Inc. is a rapidly growing Bio/Pharma company with a diversified business model participating in 3 main market segments: Specialty Pharma, Manufacturing, and Distribution. The Specialty Pharma division specializes in the formulation of generic drugs for human and veterinary usage and the development of medical devices used by oncologists and other medical professionals. The Manufacturing and Distribution divisions, manufacture, package, and distribute generic drugs, nutraceuticals, cosmetics, and functional food products for companies worldwide.
The GeoPharma, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5384
This press release may contain statements, which constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries' expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without management's control. Important factors that could cause such differences are described in the company's periodic filings with the Securities and Exchange Commission.